Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole. The newly issued patent claims further strengthen the company’s growing intellectual property estate supporting ALTO-207, a differentiated investigational therapy being developed for patients with treatment-resistant depression.
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company’s development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026.
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto’s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto’s common stock. The stock option was granted under Alto’s 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08.
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Alto Neuroscience to Participate in Upcoming Investor Conferences
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will present at the following upcoming investor conferences:
Alto Neuroscience Announces $50 Million Private Placement Financing
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $50 million, before deducting offering expenses. The financing was led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital, Vestal Point Capital, Vivo Capital, and a large biotech dedicated investor.
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression (TRD). The $50 million private placement announced today supports expanded development of ALTO-207, and the Company expects to initiate a Phase 3 study by early 2027 following Phase 3 readiness work and alignment with the FDA on the planned study design.
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience, Inc. (“Alto”) (
NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that severely impacts daily functioning and quality of life for millions of patients.
ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRONEW YORK - September 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (
NYSE: ANRO) of a class action securities lawsuit.
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANROSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANROSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRONEW YORK - September 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (
NYSE: ANRO) of a class action securities lawsuit.
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANROSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRONEW YORK - September 15, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (
NYSE: ANRO) of a class action securities lawsuit.
